| Summary: | Despite the availability of direct and indirect evidence comparing the clinical effectiveness of different anaplastic lymphoma kinase inhibitors (ALKIs), comparative cost-effectiveness of these tyrosine kinase inhibitors (TKIs) is relatively less established, particularly in the first- and second-line settings. In addition, local and international jurisdictions can benefit from evidence-based guidelines outlining the sequence of ALKIs at different stages of cancer. This report was undertaken to examine the current evidence surrounding the comparative cost-effectiveness of first-line ALKIs among patients naive to previous anaplastic lymphoma kinase (ALK) treatment (ALK-naive) as well as second-line ALKIs among patients who have been pretreated with other ALKIs and had disease progression (ALKpretreated). Evidence-based guidelines informing the sequence of ALKIs in both settings were also investigated
|
|---|